FEBUCO-40 TAB

FEBUCO-40 Tablets 

The photograph clearly shows Febuco-40 (Accott) and, importantly, the composition printed on the blister confirms the exact formulation.

Composition per film-coated tablet

IngredientQuantityPurposeFebuxostat40 mgActive uric-acid-lowering medicineExcipientsq.s.Tablet manufacturing and stabilityColour: Titanium Dioxide IP—Tablet colouring/opacification

The blister specifically states: “Each film-coated tablet contains: Febuxostat 40 mg; Excipients q.s.; Colour: Titanium Dioxide.” (Pharmacy Products Kenya)

1. Febuxostat — 40 mg

• Drug class: Xanthine oxidase inhibitor.

• It inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine into uric acid.

• This reduces production of uric acid and therefore lowers serum urate levels.

• It is used for long-term management of hyperuricemia associated with gout, rather than as a painkiller for an acute gout attack. (Pharmacy Products Kenya)

Important: Febuxostat is generally used continuously to maintain uric acid at the target level. Starting urate-lowering treatment can sometimes precipitate a gout flare initially, so doctors may prescribe additional flare prophylaxis.

2. Excipients — q.s.

q.s. = quantum satis, meaning “quantity sufficient” to make the finished tablet.

The exact individual excipients and their amounts are not listed on the visible blister. Therefore, I would not assume ingredients such as lactose, microcrystalline cellulose, starch or magnesium stearate for this specific Accott product. Different manufacturers use different excipient systems. For example, other febuxostat 40-mg products can contain microcrystalline cellulose, lactose, croscarmellose sodium, hydroxypropyl cellulose, silicon dioxide and magnesium stearate. (DailyMed)

3. Titanium Dioxide IP

Titanium dioxide is listed on your blister as the colour/opacifying agent. It is used in the film coating to give the tablet its white/opaque appearance.

Main therapeutic action

Febuco-40 → Febuxostat 40 mg → inhibits xanthine oxidase → ↓ uric-acid production → ↓ serum uric acid → helps prevent urate crystal deposition and recurrent gout complications.

Important precautions

• It is a prescription urate-lowering medicine, not a conventional painkiller.

• It should be taken at the dose and duration prescribed.

• Do not start, stop or change the dose solely based on the current uric-acid reading without medical advice.

• Febuxostat has important cardiovascular safety considerations in some patients, particularly those with established cardiovascular disease.

• It can interact significantly with medicines such as azathioprine and mercaptopurine.

• Liver-function monitoring may be appropriate during treatment.

In short

FEBUCO-40 = Febuxostat 40 mg per film-coated tablet + excipients q.s. + Titanium Dioxide as colour. (Pharmacy Products Kenya)